The US FDA has approved the revakinagene taroretcel implant, an allogeneic encapsulated cell-based gene therapy indicated for treating adults with idiopathic macular telangiectasia type 2 (MacTel). This implant is designed to continuously deliver therapeutic doses of ciliary neurotrophic factor to the retina, helping to slow disease progression. Notably, it is the first and only FDA-approved treatment for MacTel.
Clinical evidence In clinical trials, the implant significantly slowed the loss of macular photoreceptors in patients over 24 months. Dosage and administration Available for intravitreal implantation One single-dose implant Contraindications Ocular or periocular infections Known hypersensitivity to endothelial serum-free media Warnings and precautions Severe vision loss, infectious endophthalmitis, retinal tears and/or detachment, vitreous hemorrhage, implant extrusion,…
